Scott Glaser | Director Antibody Therapeutics
Genomics Institute of the Novartis Research Foundation

Scott Glaser, Director Antibody Therapeutics, Genomics Institute of the Novartis Research Foundation

Scott is Director of the Antibody Therapeutics group at GNF. His group is responsible for a broad range of platform activities associated with early to late stage antibody drug discovery. Prior to joining GNF, Scott was Sr. Director and Site Head for Pfizer’s Centers for Therapeutic Innovation (CTI) in La Jolla and had positions of increasing responsibility in the nine years prior at Biogen Idec where he was Director of Antibody Therapeutics. Scott received his Ph.D. in Molecular Biology and Biochemistry from UC Irvine and his B.A. from UC San Diego. He completed his post-doctoral training at Protein Design Labs in Mountain View, CA.

Appearances:



FOB SD Antibodies Day 1 @ 11:30

Plenary roundtable session

12 senior level tables hosted by thought leaders on key challenges and opportunities in antibody drug discovery and development. Participants are invited to join the group discussions on a topic of importance to them. The round table session will have two rotations, each lasting 30 minutes.

Table 3: Strategies for generating antibodies to challenging targets

last published: 12/Nov/18 11:05 GMT

back to speakers